What is Microbion?
Founded in 2000 and headquartered in Bozeman, Montana, Microbion is dedicated to pioneering a new class of microbial bioenergetic inhibitors. These compounds are engineered to combat challenging and resistant infections, addressing a critical unmet need in infectious disease treatment. The company's focus on this novel therapeutic approach positions it at the forefront of antimicrobial innovation, aiming to provide solutions where traditional treatments have become ineffective.
How much funding has Microbion raised?
Microbion has raised a total of $46.5M across 6 funding rounds:
Private Equity
$932K
Private Equity
$1.2M
Unspecified
$100K
Private Equity
$25M
Other Financing Round
$17.1M
Private Equity
$2.1M
Private Equity (2010): $932K, investors not publicly disclosed
Private Equity (2012): $1.2M, investors not publicly disclosed
Unspecified (2014): $100K supported by Undisclosed
Private Equity (2016): $25M featuring GF Securities and Quark Venture
Other Financing Round (2020): $17.1M backed by Carb-X and Cystic Fibrosis Foundation
Private Equity (2022): $2.1M with participation from MTEC companies
Key Investors in Microbion
MTEC companies
MTEC companies is dedicated to advancing medical innovation by facilitating the rapid deployment of innovative medical technologies that enhance the health of both military personnel and civilians. The consortium serves federal agencies, innovators, service providers, and healthcare investors by providing access to funding, expertise, and resources necessary for the development and delivery of medical technologies.
GF Securities
GF Securities is a financial services company that provides a range of investment banking, brokerage, and asset management services. Their involvement suggests a strategic interest in the growth and commercialization potential of Microbion's technology.
Carb-X
Carb-X is a global non-profit accelerator that funds the development of new antibiotics and other life-saving products to combat dangerous drug-resistant bacteria. Their investment in Microbion highlights the company's potential to address the urgent global challenge of antimicrobial resistance.
What's next for Microbion?
With its recent major strategic investment, Microbion is poised to accelerate its clinical development pipeline and further validate its unique therapeutic platform. The substantial capital infusion, indicated by $46.5M, suggests a company in a scaling phase, likely focusing on advancing its lead candidates through rigorous clinical trials and expanding its research and development capabilities. This strategic financing is expected to bolster Microbion's efforts to bring its innovative treatments to patients suffering from difficult-to-treat infections, potentially marking a significant advancement in antimicrobial therapy.
See full Microbion company page
